Early Warning Signs of Blood Cancer Discovered

Topic: Health

Researchers at the Wellcome Sanger Institute found that genetic changes can help doctors predict which patients with chronic blood cancer will develop more severe conditions. They analyzed data from 30 patients and discovered distinct patterns of evolution among those whose disease remained stable and those whose disease progressed.

Chronic blood cancers, also known as myeloproliferative neoplasms (MPNs), are rare and long-lasting diseases that begin in the bone marrow. In people with MPNs, the bone marrow makes certain blood cells in an uncontrolled way.

Around 40,000 people in the UK are living with MPNs, and approximately 4,000 new cases are diagnosed each year. These cancers often progress slowly, starting with mutations that arise very early in life, followed by additional mutations that accumulate over several decades. Most MPNs are associated with mutations in the JAK2, CALR or MPL genes.

The researchers combined genetic analysis with detailed clinical records to investigate how chronic blood cancers can develop over several decades. They found that people whose disease remained clinically stable tended to have genetically 'steady' blood cell populations that acquired few or no additional mutations. By contrast, patients whose disease progressed developed new DNA changes over time.

The results suggest that progression in chronic blood cancers may be biologically 'encoded' years before a patient's condition visibly deteriorates. Mutations linked to future progression may be detectable long before symptoms worsen or standard clinical tests reveal a major change.

Why It Matters

This discovery can help doctors improve diagnoses, monitor patients more accurately, and assess how treatments are working. It can also help identify signs of progression years before symptoms become obvious, which can lead to better treatment outcomes for patients with chronic blood cancer.

Key Facts

• Around 40,000 people in the UK are living with MPNs, and approximately 4,000 new cases are diagnosed each year.
• Most MPNs are associated with mutations in the JAK2, CALR or MPL genes.
• The researchers analyzed data from 30 patients and discovered distinct patterns of evolution among those whose disease remained stable and those whose disease progressed.
• Mutations linked to future progression may be detectable long before symptoms worsen or standard clinical tests reveal a major change.
• This discovery can help doctors improve diagnoses, monitor patients more accurately, and assess how treatments are working.

Key Terms

Myeloproliferative neoplasms (MPNs)

A group of rare, long-lasting blood cancers that begin in the bone marrow.

Genetic 'steady' blood cell populations

Blood cell populations with few or no additional mutations over time.

DNA changes

Mutations in DNA that can affect how cells grow and divide.

Implications

This discovery can help doctors improve diagnoses, monitor patients more accurately, and assess how treatments are working. It can also help identify signs of progression years before symptoms become obvious, which can lead to better treatment outcomes for patients with chronic blood cancer.